- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04863664
Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.
The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Garran, Australia, 2605
- LEADR: Canberra Hospital
-
-
Queensland
-
Chermside, Queensland, Australia, 4032
- LEADR: The Prince Charles Hospital
-
-
South Australia
-
Ashford, South Australia, Australia, 8032
- LEADR: Ashford Hospital
-
Norwood, South Australia, Australia, 5000
- LEADR: Royal Adelaide
-
-
-
-
Mitterweg
-
Krems, Mitterweg, Austria, 3500
- LEADR: Universitätsklinikum Krems
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N1
- LEADR: University of Calgary
-
-
Ontario
-
Newmarket, Ontario, Canada, L3Y8C3
- LEADR: Southlake Regional Health Centre
-
-
Quebec
-
Québec City, Quebec, Canada, G1V 4G5
- LEADR: Institut Universitaire de Cardiologie et de Pneumologie de Quebec
-
-
-
-
-
Chengdu, China
- LEADR: West China Hospital of Sichuan University
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030000
- LEADR: Shanxi Cardiovascular Hospital
-
-
-
-
-
Copenhagen, Denmark, 2100
- LEADR: Rigshospitalet
-
-
-
-
-
La Tronche, France, 38700
- LEADR: Centre Hospitalier Universitaire de Grenoble - Site Nord
-
Rouen, France, 76031
- LEADR: CHU Hôpitaux de Rouen - Hôpital Charles Nicolle
-
-
-
-
-
Bielefeld, Germany, 33604
- LEADR: Klinikum Bielefeld Kardiologie
-
-
-
-
-
Hong Kong, Hong Kong
- LEADR: Queen Mary Hospital
-
Lai Chi Kok, Hong Kong, 999077
- LEADR: Princess Margaret Hospital
-
-
-
-
-
Bergamo, Italy, 24127
- LEADR: Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
-
-
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japan, 802-8555
- LEADR: Kokura Memorial Hospital
-
-
Osaka
-
Suita, Osaka, Japan, 564-8565
- LEADR: National Cerebral and Cardiovascular Center
-
-
Tokyo
-
Shinjuku-Ku, Tokyo, Japan, 162-8666
- LEADR: Tokyo Women's Medical University Hospital
-
-
-
-
-
Kuala Lumpur, Malaysia, 50400
- LEADR: Institut Jantung Negara - National Heart Institute
-
-
-
-
-
Carnaxide, Portugal, 2790-134
- LEADR: Centro Hospitalar de Lisboa Ocidental, E.P.E. Hospital de Santa Cruz Cardiology
-
-
-
-
-
Belgrad, Serbia
- LEADR: Klinicki Centar Srbije Pejsmejker centar
-
-
-
-
-
Singapore, Singapore
- LEADR: Ng Teng Fong General Hospital
-
-
-
-
-
L'Hospitalet De Llobregat, Spain
- LEADR: Hospital Universitari Bellvitge
-
Valencia, Spain, 46026
- LEADR: Hospital Universitario y Politécnico La Fe
-
-
-
-
-
London, United Kingdom, W12 0HS
- LEADR: Imperial College Healthcare NHS Trust - Hammersmith Hospital
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- LEADR: Heart Center Research
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- LEADR: Hartford Hospital
-
-
Florida
-
Tampa, Florida, United States, 33606
- LEADR: University of South Florida
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- LEADR: Minneapolis Heart Institute Foundation
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- LEADR: Saint Luke's Mid America Heart Institute
-
Saint Louis, Missouri, United States, 63110
- LEADR: Washington University School of Medicine
-
-
New Jersey
-
Voorhees, New Jersey, United States, 08034
- LEADR: Lourdes Cardiology Services
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87108
- LEADR: Presbyterian Heart Group
-
-
New York
-
Bay Shore, New York, United States, 11030
- LEADR: South Shore University Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45202
- LEADR: TriHealth Hatton Research Institute
-
Cleveland, Ohio, United States, 44195
- LEADR: Cleveland Clinic
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- LEADR: Lehigh Valley Hospital - Cedar Crest
-
Philadelphia, Pennsylvania, United States, 19104
- LEADR: Hospital of the University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- LEADR: The Children's Hospital of Philadelphia
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- LEADR: Vanderbilt University medical Center
-
-
Texas
-
Austin, Texas, United States, 78705
- LEADR: Texas Cardiac Arrhythmia Research Foundation
-
Fort Worth, Texas, United States, 76104
- LEADR: Texas Health Fort Worth Hospital
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- LEADR: University of Virginia Medical Center
-
Richmond, Virginia, United States, 23298
- LEADR: Virginia Commonwealth University Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
LEADR Inclusion Criteria:
Subject meets current clinical practice guidelines for implantation of ICD or CRT-D and will undergo one of the following:
- de novo Medtronic CRT-D system implant
- de novo Medtronic ICD system implant (single or dual chamber)
- Subject has, per local law and requirements, the minimum age for autonomously signing an ICF (minimum age of 18 years)
- Subject is willing to undergo implant defibrillation testing if requested.
- Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.
LEADR Exclusion Criteria:
- Subject is unwilling or unable to personally provide Informed Consent.
- Subject has contraindications for standard RV transvenous lead placement (e.g., mechanical right heart valve).
- Subject is contraindicated for ≤1 mg dexamethasone acetate.
- Subject has a life expectancy of less than 12 months
For subject undergoing defibrillation testing the following medical conditions exclude them:
- Pre-existing or suspected pneumothorax during implant
- Current intracardiac left atrial or left ventricular (LV) thrombus
- Severe aortic stenosis
- Severe proximal three-vessel or left main coronary artery disease without revascularization
- Unstable angina
- Ejection Fraction less than 25%
- Recent stroke or transient ischemic attack (within the last 6 months)
- Known inadequate external defibrillation
- Any other known medical condition not listed that precludes their participation in the opinion of the investigator
- Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.
- Subject with any exclusion criteria as required by local law (e.g., age or other).
- Pregnant women or breastfeeding women, or women of childbearing potential and who are not on a reliable form of birth regulation method or abstinence
- Subject with an existing pacemaker (including transcatheter pacing system), ICD, or CRT device or leads
- Subject with any evidence of active infection or undergoing treatment for an infection
- Recent (or planned) cardiac surgery or stenting less than 1 month before implant
- End stage renal disease
- Subjects with NYHA IV classification
- Subjects with a transplanted heart
- Subjects with previously extracted leads
- Subjects with Left Ventricular Assist Device
LEADR LBBAP Inclusion Criteria:
Subject meets current local clinical practice guidelines for implantation of ICD (single or dual chamber) or CRT-D system and will undergo one of the following:
a) De novo Medtronic ICD system implant (single or dual chamber) or b) De novo Medtronic CRT-D system implant and is intended to also undergo LV lead implant (for patients indicated for CRT-D according to locally approved indications/indications)
- Subject is 12 years of age or older and also is greater than 30 kg in weight at time of enrollment, has cardiac anatomy conducive to RV coil placement, and is allowed to participate in study per local law and requirements. Subjects from 12 years of age until adult also have a separate indication for pacing or CRT or are anticipated to develop one.
- Subject provides written authorization and/or consent per institution and geographical requirements.
- Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up
- Subject is willing to undergo implant defibrillation testing if requested
LEADR LBBAP Exclusion Criteria:
- Subject has contraindication for screw-in active fixation transvenous lead placement (e.g., mechanical right heart valve)
- Subject is contraindicated for ≤1 mg dexamethasone acetate
- Subject has a life expectancy of less than 12 months
For subject undergoing defibrillation testing the following medical conditions exclude them:
- Pre-existing or suspected pneumothorax
- Current intracardiac left atrial or LV thrombus
- Severe aortic stenosis
- Severe proximal three-vessel or left main coronary artery disease without revascularization
- Unstable angina
- Recent stroke or transient ischemic attack (within the last 6 months)
- Known inadequate external defibrillation
- Any other known medical condition not listed that precludes their participation in the opinion of the investigator
- Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
- Subject is pregnant or breastfeeding, or subject is of childbearing potential and not on a reliable form of birth regulation method or abstinence
- Subject with an existing pacemaker (including transvenous and transcatheter pacing system), ICD (transvenous) or CRT-D (transvenous) device or leads
- Subject with previous subcutaneous ICD (S-ICD), extravascular ICD (EV ICD) or Implantable Cardiac Monitor explanted within 30 days before implant
- Subject with any evidence of active bacterial infection or undergoing treatment for a bacterial infection within the last 30 days
- Recent (or planned) cardiovascular intervention within 30 days before or after implant, such as cardiac surgery, cardiac ablation, Percutaneous Coronary Intervention (PCI), or temporary cardiac pacing for >12 hours
- Subjects with end stage renal disease
- Subjects with NYHA IV classification
- Subjects with a transplanted heart or on the waiting list for a heart transplant
- Subjects with previously extracted leads
- Subjects with Left Ventricular Assist Device
- Subjects that are vulnerable adults
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention/Treatment (LEADR)
Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing
|
Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
|
Experimental: Intervention/Treatment (LEADR LBBAP)
Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing
|
Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LEADR: Estimate the rate of major Lead complication-free rate at 6 months
Time Frame: Implant to 6 Months
|
Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.
|
Implant to 6 Months
|
LEADR: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead
Time Frame: Day 1
|
Defibrillation testing will be completed in a subset of subjects at implant.
|
Day 1
|
LEADR LBBAP: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead
Time Frame: Day 1
|
Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.
|
Day 1
|
LEADR LBBAP: The lead-related major complication rate at 3-months
Time Frame: Implant to 3 Months
|
Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.
|
Implant to 3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LEADR: Estimate the fracture-free rate of the Next Generation ICD lead
Time Frame: up to 24 months
|
Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.
|
up to 24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: George Crossley, MD, Vanderbilt University (LEADR)
- Principal Investigator: Pugazhendhi Vijayaraman, MD, Geisinger Medical Center (LEADR LBBAP)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDT19004 / MDT22048
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tachyarrhythmia
-
Medtronic Bakken Research CenterMedtronicCompletedAtrial Fibrillation | Atrial Tachyarrhythmia
-
University of California, San DiegoNational Heart, Lung, and Blood Institute (NHLBI)CompletedAtrial Fibrillation | Atrial TachyarrhythmiaUnited States
-
Hartford HospitalUnknown
-
Biotronik SE & Co. KGCompletedVentricular TachyarrhythmiaGermany, Sweden
-
Sheba Medical CenterCompletedVentricular TachyarrhythmiaIsrael
-
Boston Scientific CorporationCompletedVentricular TachyarrhythmiasNew Zealand
-
Medtronic Bakken Research CenterMedtronicCompleted
-
Emory UniversityCompletedBradycardia, Atrial TachyarrhythmiaUnited States
-
University of California, San DiegoCompletedVentricular TachyarrhythmiasUnited States
-
Ochsner Health SystemBoston Scientific CorporationCompletedVentricular Fibrillation | Ventricular Tachycardia | CardiomyopathyUnited States
Clinical Trials on Defibrillation (RV Implant)
-
Associates in Cardiology, PAMedtronicUnknownTachycardia, Ventricular | Heart Failure, CongestiveUnited States
-
University Hospital of FerraraRecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Left Bundle-Branch Block | Bundle-Branch Block | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Dysfunction | Atrioventricular Block | Heart Failure, Systolic | Ventricular Arrythmia | Heart Failure,Congestive | Bradyarrhythmia | Heart Arrhythmia | Reduced... and other conditionsItaly
-
Boston Scientific CorporationCompletedCardiac Resynchronization TherapyUnited States
-
Singapore General HospitalZoll Medical CorporationCompletedDeath | Ventricular Fibrillation | Ventricular Tachycardia | Sudden Cardiac Death | Cardiac EventSingapore
-
Medtronic Bakken Research CenterCompletedCardiac Pacing Indication classI/IIa According AHA/ACCSpain
-
Kestra Medical Technologies, Inc.RecruitingSudden Cardiac ArrestUnited States
-
Zoll Medical CorporationCompletedSudden Cardiac Death | Cardiac Event | Cardiac Arrythmias | Left Ventricular DysfunctionFrance
-
University of ChicagoRecruitingHeart Failure | Right Ventricular Dysfunction | Right Ventricular FailureUnited States
-
Lawson Health Research InstituteMedtronicUnknown
-
Sunnybrook Health Sciences CentrePeel Regional Paramedic Service; Toronto Paramedic Services; Halton Region Paramedic... and other collaboratorsCompletedVentricular FibrillationCanada